Fusion Antibodies (LON:FAB) Trading 11.8% Higher – What’s Next?

Shares of Fusion Antibodies plc (LON:FAB) were up 11.8% on Thursday . The stock traded as high as GBX 13.70 and last traded at GBX 13.70. Approximately 686,309 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 1,181,509 shares. The stock had previously closed at GBX 12.25.

Fusion Antibodies Stock Up 11.8%

The stock has a market cap of £15.57 million, a P/E ratio of -7.61 and a beta of 0.49. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The stock’s 50-day moving average is GBX 15.24 and its 200-day moving average is GBX 11.13.

Fusion Antibodies (LON:FAB) last released its quarterly earnings results on Thursday, September 4th. The company reported GBX (1.80) EPS for the quarter. Fusion Antibodies had a negative return on equity of 137.11% and a negative net margin of 195.95%. As a group, research analysts anticipate that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.